文献速递眼底病与葡萄膜炎角膜与眼表疾病眼整形与眼眶

抗PD-1/PD-L1免疫治疗相关眼部并发症的患病率与临床模式

Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.
PubMed 文献 · Am J Ophthalmol · 2019-02-15

该前瞻性病例系列纳入745例接受抗PD-(L)1治疗的患者,中重度眼部免疫相关不良事件患病率为0.4%,发病率为0.7/1000患者月;结合国家注册系统共8例,以眼内炎症最常见,局部和/或全身糖皮质激素可使多数患者症状缓解或控制。

要点

  • 抗PD-(L)1相关中重度眼部irAEs患病率0.4%,发病率0.7/1000患者月。
  • 8例中5例眼内炎症、2例眼表疾病、1例眶肌病,5例伴眼外irAEs。
  • 4例因眼部irAEs永久停用抗PD-(L)1,7/8例经激素治疗缓解或控制。

核心结论

  • 抗PD-(L)1相关眼部并发症虽不常见,但可能威胁视力并导致治疗中断。
  • 接受ICI治疗的患者出现眼部症状时应立即由眼科医生评估。

研究设计与样本

  • 前瞻性病例系列,纳入单中心前瞻性队列及国家药物警戒注册系统2014年6月至2018年3月的中重度眼部irAEs患者。
  • 前瞻性队列共745例接受抗PD-(L)1治疗的患者,所有患者接受全面眼科评估。

主要发现

  • 745例前瞻性队列中3例发生中重度眼部irAEs,患病率0.4%,发病率0.7/1000患者月。
  • 国家注册系统另报告5例中重度眼部irAEs,合计8例。
  • 8例中5例表现为眼内炎症,2例眼表疾病,1例眶肌病。
  • 5例(62.5%)合并眼外irAEs。
  • 4例因眼部irAEs永久停用抗PD-(L)1。

关键数值与推荐

  • 中重度眼部irAEs患病率0.4%(3/745),发病率0.7/1000患者月。
  • 8例中眼内炎症5例、眼表疾病2例、眶肌病1例。
  • 5例(62.5%)合并眼外irAEs。
  • 4例因眼部irAEs永久停用抗PD-(L)1。
  • 7/8例经局部和/或全身糖皮质激素治疗缓解或控制。

临床怎么用

  • 接受抗PD-(L)1治疗的患者出现眼部症状时应立即转诊眼科评估。
  • 中重度眼部irAEs可考虑局部和/或全身糖皮质激素治疗。
  • 需警惕眼部irAEs导致抗PD-(L)1永久停药的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immune checkpoint inhibitors (ICI) targeting the programmed cell death protein 1 (PD-1), or its ligand PD-L1, are the mainstay of metastatic cancer treatment. Patients receiving these treatments may develop immune-related adverse events (irAEs). This study aimed to estimate the prevalence and describe the clinical patterns of moderate-to-severe ocular irAEs-associated with anti-PD-(L)1 treatment. DESIGN: Prospective case series. METHODS: This study included patients recruited via (1) a single-center prospective cohort and (2) a national pharmacovigilance registry between June 2014 and March 2018, and focused on patients with moderate-to-severe ocular irAEs following anti-PD-(L)1. All patients underwent a comprehensive ophthalmologic assessment. The main outcome measure was the prevalence of moderate-to-severe ocular irAEs. RESULTS: Of a total of 745 patients included in the prospective cohort, 3 developed moderate-to-severe ocular irAEs, providing a prevalence of 0.4% and an incidence of 0.7 per 1000 patient-months of treatment. An additional 5 cases of moderate-to-severe ocular irAEs were reported through the national registry. From these 8 patients, 5 presented with intraocular inflammation, 2 with ocular surface disease, and 1 with orbital myopathy. Five patients (62.5%) experienced additional extraophthalmologic irAEs. Ocular irAEs led to permanent discontinuation of anti-PD-(L)1 in 4 patients. Treatment by local and/or systemic corticosteroids allowed resolution or control of the ocular symptoms in 7 of 8 patients. CONCLUSION: Although uncommon, anti-PD-(L)1-associated ocular complications may be sight-threatening and lead to discontinuation of anti-PD-(L)1 treatments. Patients complaining of eye problems while receiving ICI treatment should immediately be seen by an ophthalmologist.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bitton K, Michot JM, Barreau E, et al. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. Am J Ophthalmol. 2019. PMID: 30772350. doi:10.1016/j.ajo.2019.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。